IP Archives of Cytology and Histopathology Research

Print ISSN: 2581-5725

Online ISSN: 2456-9267

CODEN : IACHCL

IP Archives of Cytology and Histopathology Research (ACHR) open access, peer-reviewed quarterly journal publishing since 2016 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination more...


  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 55

PDF Downloaded: 28

Gupta, Jaiswal, Tripathi, and Venkatesh: Observational study on serum markers and circulating tumor cells in ovarian cancer


Introduction

Ovarian malignancies constitute 3% of all malignancies in the females and is the fifth most common cause of death due to cancer in women.1 In most of the population-based cancer registries in India, ovarian cancer is the third leading site of cancer among women, trailing behind cervix and breast cancer. The age-adjusted incidence rates of ovarian cancer vary between 5.4 and 8.0 per 100,000 population in different parts of India.2

Primary ovarian tumors may arise from surface epithelial cells, germ cells, or sex cord stromal cells, so have been classified accordingly. Secondary tumours are implanted on to the ovary from somewhere else.

Dualistic model of epithelial ovarian cancer (EOC), which divides epithelial ovarian carcinomas into two broad categories, designated type I and type II. Prototypic type I tumour is low grade serous serous carcinoma, which has a high frequency of KRAS and BRAF mutations but no TP53 mutations and prototypic type II tumor is high grade serous carcinoma which is characterized by high level of genetic instability and harbours TP53 mutations in nearly all cases.

The main problem with the epithelial ovarian cancers is that these patients (almost 75%) are diagnosed on advanced stages (FIGO III/IV). By the time these are diagnosed, metastases have already occurred by transperitoneal, hematogenous and lymphatic routes.3, 4

Diagnostic tools

Molecular methods

A. Polymerase Chain Reaction: Molecular diversity exists within specific histological subtypes of EOC, between different tumors of an individual patient, as well as within individual tumors. EOC are classified as either type I or type II tumor on molecular basis with implications on disease pathogenesis and prognosis. Association of various genes alteration with the EOC I have been studied like BRAF, KRAS PIK3CA, CTNNB1, & CDKN2A and type II ovarian malignancies with BRCA1, BRCA2, MYC, MECOM, CCNE1, PRCK1, NOTCH3, KRAS, ERBB2, KIT & EGFR.5, 6, 7, 8

For the early diagnosis of EOC, multiplex nested methylated specific polymerase chain reaction (PCR) is another method to detect the methylation level of serum and tissue samples in patients with ovarian carcinoma and the results compared with the detection with CA125.9 

B. Circulating Tumor Cells (CTC) and Cell free DNA (cfDNA): Tumor-derived DNA has been identified in the body fluids of patients with a variety of cancers, including colorectal, head and neck, lung, bladder, kidney, and prostate.10, 11, 12, 13, 14 Identifying tumor-specific molecular alterations in urine, saliva, sputum, and stool can be a noninvasive diagnostic test for cancer. 15, 16, 17, 18

Liquid biopsy, involves the collection and analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating cell-free microRNAs (cfmiRNAs), and exosomes.16, 17

The use of cfDNA as a screening method has been evaluated in cancers of renal cell, lung, testicular, colorectal, and breast origin, suggesting that it could be used as a non-invasive biomarker for a wide variety of cancer types. 18, 19, 20, 21

These cfDNAs were found to range between 0.5 to 21 kb in length, with a plasma concentration ranging from 0.15 to 12 mg/mL, used as a diagnostic tool to detect different forms of cancer including hematological, colorectal and thoracic neoplasms.22 This was followed by studies that focused on identifying micrometastases in form of CTCs.23, 24, 25 Bettegowda et al. showed that these micrometastases signal can also be identified by measuring ctDNAs. 25

Serum markers

A. CA125 (Carbohydrate or Carcinoma Antigen) is a high molecular weight glycoprotein. Serum CA125 levels are routinely ordered in women with adnexal masses, and levels less than 35 U/ml are considered to be normal. However, CA125 has low specificity as it is also increased in benign endometriosis, endometrial and cervical adenocarcinoma, breast and colon cancer etc. 26, 27

B. Serum HE4 (Human Epididymis protein) is used to monitor recurrence/progressive disease in patients with epithelial ovarian malignancy. Normally female genital tract and epididymal epithelium secrete HE4. Its over expression is seen in serous and endometrioid ovarian malignancies. 26

Steps and methods

Study design

Comparative observational study.

Sample size

64 (95% CI; 5% error; prevalence of 5%).

Duration of study

One year.

The study was carried out in the department of Pathology, in collaboration with Microbiology and Obstetrics and Gynaecology, was approved by the Institutional Ethical Committee and review board. Patients of clinically diagnosed and radiologically suggested ovarian mass were included in study. Final histopathological diagnosis was recorded in all cases.

Patients with a history of cancer, either gynecological or from other systems or inflammatory diseases as a side diagnosis were excluded.

The blood samples were collected twice, once before any invasive procedures or before start of any medical treatments, and second between 4th-7th day post surgery. Clinical information including demographic information, serum CA 125 and HE4 levels, tumor stage, histology, and ultrasonographic finding was obtained from the patients’ medical records and pathology reports. Serum markers were tested and analysed in pre-operative and post-operative samples, in all cases.

The tumor volume in epithelial ovarian cancers was obtained before any tumor reduction by Radiology. CA 125 was measured before any treatment or surgery. The cut off value of 35 U/mL was used to distinguish between normal and pathologic cases.

Sample collection, storage and steps

A total of 5 mL of venous blood sample were collected. These samples were transferred to an 8 mL gel serum separator tube (BD—Becton, Dickinson and Company) and kept at room temperature for coagulation. Subsequently, the samples were centrifuged for 10 min at 1000 g. The samples were processed within 2 hours after collection to prevent loss of cell-free DNA for PCR. 23, 24

The serum of all patients were collected and DNA was extracted by Invitrogen DNA Mini Kits (USA, Invitrogen company), with all operations being conducted strictly according to the kit instructions. PCR was performed for 3 genes that is Cyclophilin, SFRP5 and APC.

Steps performed were DNA Extraction, Preparation of lysate: (Manufacturer’s instructions were followed), Binding of DNA, Washing of DNA, Elution of DNA and finally Agarose gel electrophoresis was performed to analyse results.

Conventional PCR cycles and thermal conditions

Conditions used for PCR were “initial denaturation at 95°C for 10 min followed by 40 cycles of 1min denaturation at 95°C, 1min annealing at 55°C, and 1min elongation at 72°C. The last cycle was followed by a final extension of 10min at 72°C.

PCR was performed with prepublished primers for 3 genes, cyclophilin with forward sequence 5’-TTCTTCATCACCTATGGCAAAC-3’ & reverse primer 5’- GCAACTTCTCCAACTCATCTAG-3’, SFRP5 WITH FORWARD primer 5’- CAGATGTGCTCCAGTGACTTTG-3’ & reverse primer 5’- AGAAGAAAGGGTAGTAGAGGGAG-3’ and APC with forward primer 5’-GAGACAGAATGGAGGTGCTGC-3’ &reverse primer 5’-GTAAGATGATTGGAATTATCTTCT-3’. PCR products were identified by 2% agarose gel electrophoresis (AE), and DNA was regarded to be qualified when there were significantly visible products. (seephotoplates).

Agarose gel electrophoresis

To visualize, 5μl of the PCR amplicon was loaded with gel loading dye (Thermo Fisher Scientific, India) in 1.5 % agarose gel containing 0.5µl/ml of ethidium bromide (0.5mg/ml, Medox biotech India Pvt Ltd) along with molecular weight marker (100bp DNA ladder; Bangalore Genei, India) followed by electrophoresis at 80 V for 2 h and multiple amplified DNA was analysed by 264nm wavelength UV transilluminator and gel was documented.(images attached at photoplates).

A sample would be labelled as CTC positive if at least one of 3 gene marker panel is found to be over expressed.

Detection of serum CA125

Serum CA125 concentration was detected by ELISA CA125 Test principle: The CA125 quantitative test is based on a solid phase enzyme linked immunosorbent assay, measured spectrophotometrically at 450nm. The concentration of CA125 is directly proportional to intensity of the sample.

Detection of Human Epididymal Protein 4

Serum HE4 was detected by sandwich ELISA

Testprinciple

The optical density (OD) measured with spectrophotometry at a wavelength of 450 nm ± 2 nm is proportional to the concentration of Human HE4 calculated in samples by comparing the OD of the samples with the standard curve.

Results

64 cases fulfilling the inclusion criteria and giving their consent for inclusion in the study were enrolled as subjects of the present study. However, 5 samples were discarded due to either inadequacy or hemolysis. All the calculations are based on 59 samples studied for all parameters.

On the Serum samples which we procured, after DNA extraction (Invitrogen mini kit, USA) we performed conventional PCR to amplify the extracted DNA and further subjected them to electrophoresis for the identification(expression) of 3 genes i.e Cyclophillin, APC and SFRP5, however, none of the genes expressed in either benign or malignant cases, in either pre or post operative samples.

Age of patients enrolled in the study ranged between 12 to 85 years, mean age of patients was 38.24±16.06 years. Majority of the cases enrolled in the study were aged above 30 years (66.1%).

50(84.7%) were married and only 9(15.3%) cases were unmarried.

Majority of the cases enrolled in the study were multipara to grandmultipara (P2 and above; n=39, 66.1%), only 6.8% were Unipara and rest were Nullipara (27.1%).

Size of lesions of the patients enrolled in the study ranged from 1.78 to 31.0 cm, mean size of lesions was found to be 8.64±5.91 cm. Only 35.6% cases had lesion size ≤5 cm, 32.2% each of the patients had lesion size 5-10 cm and >10 cm.

Majority of the patients had unilateral involvement (71.2%) rest 28.8% had bilateral involvement.

Cystic echotexture on imaging was observed in majority of the cases (54.2%), solid echotexture was observed for 13.6% in rest 32.2% cases mixed echotexture was observed.

Table 1

Histopathological Diagnosis

S.No

Diagnosis

No.

%

1.

Benign

43

72.9

Cystic lesion

5/43 (11.6%)

5

8.5

Serous cyst

15/43 (34.9%)

15

25.4

Mature cystic

7/43 (16.3%)

7

11.9

Follicular cystic

5/43 (11.6%)

5

8.5

Hemorrhagic cyst

4/43 (9.34%)

4

6.8

Others (Benign)

7/43 (16.3%)

7

11.9

2.

Malignant

16

27.1

Serous cystadenoCa

10/16 (62.5%)

10

16.9

Others    (Malignant)

6/16 (37.5%)

6

10.2

Table 2

A. Evaluation of mean preoperative HE-4 and CA-125 levels for their diagnostic efficacy

Diagnostic domain

N

CA-125 (U/ml)

HE-4 (pmol/l)

Mean

SD

Mean

SD

Benign vs Malignant

Benign

43

62.49

109.91

72.68

69.69

Malignant

16

902.39

1792.10

744.31

405.21

Statistical significance

‘t’=3.104; p= 0.003 (Sig)

‘t’=10.603; p<0.001

Pre-operatively, patients with Malignant lesions as compared to Benign lesions had significantly higher CA-125 levels (902.39±1792.10 vs. 62.49±109.91 U/ml) as well as higher HE-4 levels (744.31±405.21 vs. 72.68±69.69 pmol/l).Table 2A.

Table 0

Table 2B: Evaluation of mean Post-operative HE-4 and CA-125 levels for their diagnostic efficacy

Diagnostic domain

n

CA-125 (U/ml)

HE-4 (pmol/l)

Mean

SD

Mean

SD

Benign vs Malignant

Benign

43

27.60

25.86

35.82

28.02

Malignant

16

54.09

39.93

150.11

88.20

Statistical significance

‘t’=2.994; p=0.004 (Sig)

‘t’=7.616; p<0.001 (Sig)

Post-operatively too, patients with Malignant lesions as compared to Benign lesions had significantly higher CA-125 levels (54.09±39.93 vs. 27.60±25.86 U/ml) as well as higher HE-4 levels (150.11±88.20 vs. 35.82±28.02 pmol/l).Table 2B.

Table 0

Table 2C: Change in Pre-Operative HE4 and CA-125 levels (Paired ‘t’ test)

CA-125 (U/ml)

HE-4 (pmol/l)

Mean Ch.

SD

% Ch.

‘t’

‘p’

Mean Ch.

SD

% Ch.

‘t’

‘p’

Benign

-34.89

91.56

-55.83

-2.499

0.016

-36.85

53.43

-50.70

-4.523

<0.001

Malignant

-848.3

1766.3

-94.01

-1.921

0.074

-594.2

347.1

-79.83

-6.848

<0.001

Decline in pre-operative CA-125 and HE-4 was observed in patients with benign as well as malignant lesions.Table 2C.

Changes were found to be significant statistically for both the markers, in benign lesions while significant statistically only for HE-4 marker, in malignant lesionsFigure 1

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ea970ffc-f6a8-417d-9c49-e4c22472a3c5image1.png
Table 0

Table 2D Comparative parameters of HE4 and CA125 at the expected cut off values (Receiver Operator Characteristic Curve)

Parameter

Area under curve (95% CI)

Projected cut-off value

Projected Sensitivity

Projected Specificity

CA-125

0.782 (0.63-0.94)

≥92.35

75.0%

81.4%

HE-4

0.926 (0.84-1.01)

≥102.62

87.5%

70.1%

On receiver-operator characteristic analysis, the area under curve was found to be 0.782 for CA-125 and 0.926 for HE-4. The difference between two was not significant statistically (p>0.05).Table 2D.

On evaluating the regressed coordinates for different sensitivity/specificity trade-off, the cut-off value >92.35 U/ml for CA-125 and or HE-4 and cut-off value >102.62 p/mol. Sensitivity and specificity for CA-125 were found to be 75.0% & 81.4% while that for HE-4 were 87.5% & 70.1% in differentiating malignant masses and benign lesions.

Discussion

Molecular methods

Since none of our samples came out to be positive for either of the three genes (cyclophyllin, SFRP5 and APC), we probed further into literature to compare our results. Most of the related studies conclude that concentration of CTCs presented in ovarian cancer are extremely low, 1/109 blood cells or 1/106 nucleated blood cells, and hence difficult to detect. Moreover stringent procurement, storage and test conditions are demanded.3

Board et al in 2010, to detect SNV (PIK3CA) alteration by allele specific PCR in operable stage of breast cancer reported 0% (0/14) sensitivity in patients with detected ctDNA with marker positive breast cancers.28

However Shao et al. in 2015 suggested that there is a definite correlation between levels of serum cfDNA and development of ovarian cancer, but their detection is challenging.29

Ignatiadis et al. in 2015 said that ctDNA may represent an exceedingly rare subpopulation within total cell-free DNA, at levels corresponding to one genome equivalent in 5 mL of plasma (0.01% allele fraction), and may be undetectable in plasma volumes typically sampled.30

Serum markers

CA-125 levels ranged from 6.10 to 7087 units. A mean of 62.49 units/ml and SD of 109.91 in benign cases, and a mean of 902.39 units/ml and SD of 1792.10 in malignant cases was calculated, as is shown in Table 2A. The ability of CA125 in differentiating benign from malignant cases was found to be statistically significant (p=0.003). Along with USG findings, it proves to be a sensitive method to differentiate benign from malignant masses. Some studies however show that CA125 can sometimes over-diagnose benign cases like endometriosis and hence lead to unnecessary operation.

Human Epididymis 4 levels: HE4 levels ranged from 10.04 pmole/litre to 1391.08 pmole/litre.

In benign cases, a mean of 72.68 and a standard deviation of 69.69 was obtained while in malignant cases, mean was 744.31 and SD was 405.21. HE-4 lvels were found to be significantly higher in malignant cases as compared to benign (p<0.001).

Conclusion

Detection of circulating tumor DNA in ovarian cancer sera is difficult, and requires meticulous draft of multiple genes in panel to get a significant yield Serum markers must be used in conjunction with clinico-radiological findings.

Acknowledgement

I would like to express the deepest gratitude to my chief supervisor and guide Dr. Riddhi Jaiswal (M.D.) Associate Professor, Department of Pathology, KGMU, Lucknow for her constant encouragement, support and constructive criticism throughout the course of this study. I have been fortunate as I got opportunity to work under her supervision. Throughout the thesis, she handled my careless mistakes with great patience and bestowed her motherly love on me. I thank you mam for everything. Dr. Riddhi Jaiswal has been my mentor, my guide, my icon. In true sense words fail to express my heartfelt thanks.

I am highly grateful to Family and friends who supported me throughout and in most difficult times.

I am very much thankful to the patients for their cooperation and wish them good health.

Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

Source of Funding

None.

References

1 

Q Zhang G Hu Q Yang R Dong X Xie D Ma A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNAGynecol Oncol20131301132910.1016/j.ygyno.2013.04.048

2 

P Basu P De S Mandal K Ray Biswas J2 Study of ‘patterns of care’ of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern IndiaIndian J Cancer2009461283310.4103/0019-509x.48592

3 

X Cheng L Zhang Yajuan Chen and Chen Qing Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancerJ Ovarian Res20171010.1186/s13048-017-0369-5

4 

X Zhang H Lia X Yua S Li Z Lei C Li Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a BiomarkerCell Physiol Biochem201848419839410.1159/000492521

5 

V Rojas KM Hirshfield S Ganesan Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentInt J Mol Sci20161712211310.3390/ijms17122113

6 

G Singer R Oldt B G Wang D Sidransky R J Kurman Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinomaJ Natl Cancer Inst2003956484610.1093/jnci/95.6.484

7 

S Jones T L Wang R J Kurman K Nakayama V E Velculescu B Vogelstein Low-grade serous carcinomas of the ovary contain very few point mutationsJ Pathol201222634132010.1002/path.3967

8 

SM Hunter MS Anglesio GL Ryland R Sharma YE Chiew SM Rowley Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesOncotarget20156376637710.18632/oncotarget.5438

9 

N Umetani J Kim S Hiramatsu Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeatsClin Chem20065261062910.1373/clinchem.2006.068577

10 

D Sidransky T Tokino S R Hamilton K W Kinzler B Levin P Frost Identification of ras oncogene mutations in the stool of patients with curable colorectal tumorsScience19922565053102510.1126/science.1566048

11 

M S Fliss H Usadel O L Caballero L Wu M R Buta S M Eleff Facile detection of mitochondrial DNA mutations in tumors and bodily fluidsScience2000287546020179

12 

D Sidransky AV Eschenbach YC Tsai P Jones I Summerhayes F Marshall Identification of p53 gene mutations in bladder cancers and urine samplesScience19912525006706910.1126/science.2024123

13 

P Cairns M Esteller J G Herman M Schoenberg C Jeronimo M Sanchez-Cespedes Molecular detection of prostate cancer in urine by GSTP1 hypermethylationClin Cancer Res200179272730

14 

EM Swisher M Wollan SM Mahtani R Garcia BA Goff MC King Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancerAm J Obstet Gynecol20051933662710.1016/j.ajog.2005.01.054

15 

L D Mellby A P Nyberg J S Johansen C Wingren B G Nordestgaard S E Bojesen Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic CancerJ Clin Oncol2018362828879410.1200/JCO.2017.77.6658

16 

L Giannopoulou M Zavridou S Kasimir-Bauer ES Lianidou Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomesTransl Res2019205779110.1016/j.trsl.2018.10.003

17 

F Gang L Guorong Z An A Gentil-Perret G Christian T Jacques Prediction of Clear Cell Renal Cell Carcinoma by Integrity of Cell-freeUrology2010752262510.1016/j.urology.2009.06.048

18 

U Deligezer Y Eralp EE Akisik EZ Akisik P Saip E Topuz Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapyClin Chem Lab Med2008463311710.1515/CCLM.2008.080

19 

H Schwarzenbach J Stoehlmacher K Pantel E Goekkurt Detection and monitoring of cell-free DNA in blood of patients with colorectal cancerAnn N Y Acad Sci20081137190610.1196/annals.1448.025

20 

JH No K Kim KH Park YB Kim Cell-free DNA Level as a Prognostic Biomarker for Epithelial Ovarian CancerAnticancer Res2012328346771

21 

M Stroun P Anker J Lyautey C Lederrey PA Maurice Isolation and characterization of DNA from the plasma of cancer patientsEur J Cancer Clin Oncol19872367071210.1016/0277-5379(87)90266-5

22 

L Holmgren M S Reilly J Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppressionNat Med1995121495310.1038/nm0295-149

23 

H Wikman R Vessella K Pantel Cancer micrometastasis and tumour dormancyAPMIS20081167-87547010.1111/j.1600-0463.2008.01033.x

24 

M-Ha Nicola R Bizon Jjs Machado T Sollero R S Rodarte J S Nobre Breast cancer micrometastases: different interactions of carcinoma cells with normal and cancer patients’ bone marrow stromataClin Exp Metastasis20032054719

25 

C Bettegowda M Sausen R J Leary I Kinde Y Wang N Agrawal Detection of circulating tumor DNA in early- and late-stage human malignanciesSci Transl Med2014622422410.1126/scitranslmed.3007094

26 

X Cheng L Zhang Y Chen C Qing Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancerJ Ovarian Res20171017510.1186/s13048-017-0369-5

27 

S Khati R Jaiswal N Singh Evaluation of Serum HE4 in Ovarian Tumors, Its Comparison with Serum CA125 and Correlation with Histological SubtypesIndian J Gynecol Oncol201816410.1007/s40944-018-0232-7

28 

R E Board A M Wardley J M Dixon A C Armstrong S Howell L Renshaw Detection of PIK3CA mutations in circulating free DNA in patients with breast cancerBreast Cancer Res Treat20101202461710.1007/s10549-010-0747-9

29 

X Shao Y He M Ji X Chen J Qi W Shi Quantita­tive analysis of cell-free DNA in ovarian cancerOncol Lett201510634788210.3892/ol.2015.3771

30 

M Ignatiadis M Lee S S Jeffrey Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical UtilityClin Cancer Res20152121478680010.1158/1078-0432.CCR-14-1190



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article type

Original Article


Article page

181-186


Authors Details

Pravesh Gupta, Riddhi Jaiswal, Piyush Tripathi, Vimala Venkatesh


Article History

Received : 26-07-2021

Accepted : 21-08-2021

Available online : 16-09-2021


Article Metrics


View Article As

 


Downlaod Files

   








Wiki in hindi